Ian W. Flinn

Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

M. Caligiuri, I. Flinn, S. Piantadosi, 2000, Blood.

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

I. Flinn, R. Abrams, M. Borowitz, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

I. Flinn, R. Abrams, Richard J. Jones, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies

M. Grever, R. Abrams, S. Piantadosi, 1998, Bone Marrow Transplantation.

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia

M. Grever, J. Byrd, I. Flinn, 2005, Leukemia.

Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.

I. Flinn, R. Ambinder, V. Lemas, 2000, Blood.

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

I. Flinn, N. Bartlett, C. Cheah, 2020 .